<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Rahman, T.A.</td>
<td>485-492</td>
</tr>
<tr>
<td>Abe, K.</td>
<td>31-36, 55-60</td>
</tr>
<tr>
<td>Aihara, A.</td>
<td>55-60</td>
</tr>
<tr>
<td>Al-Ani, M.</td>
<td>235-241</td>
</tr>
<tr>
<td>Aller, M.-A.</td>
<td>321-322</td>
</tr>
<tr>
<td>Ameshima, S.</td>
<td>517-523</td>
</tr>
<tr>
<td>Ang, B.C.</td>
<td>73-75</td>
</tr>
<tr>
<td>Arias, J.</td>
<td>321-322</td>
</tr>
<tr>
<td>Arner, P.</td>
<td>243-253, 453-456</td>
</tr>
<tr>
<td>Ashby, M.J.</td>
<td>37-46</td>
</tr>
<tr>
<td>Abe, K.</td>
<td>31-36, 55-60</td>
</tr>
<tr>
<td>Barnes, P.J.</td>
<td>301-306</td>
</tr>
<tr>
<td>Bartlett, K.</td>
<td>307-313</td>
</tr>
<tr>
<td>Bavington, C.</td>
<td>61-71</td>
</tr>
<tr>
<td>Belcher, P.R.</td>
<td>363-368</td>
</tr>
<tr>
<td>Bennett, J.L.</td>
<td>183-187</td>
</tr>
<tr>
<td>Bennett, M.A.</td>
<td>21-29</td>
</tr>
<tr>
<td>Bergelson, B.A.</td>
<td>261-268</td>
</tr>
<tr>
<td>Bernardi, L.</td>
<td>345-355</td>
</tr>
<tr>
<td>Bettany, J.</td>
<td>105-111</td>
</tr>
<tr>
<td>Bhaskar, A.</td>
<td>315-319</td>
</tr>
<tr>
<td>Bing, C.</td>
<td>499-505</td>
</tr>
<tr>
<td>Blum, M.</td>
<td>379-384</td>
</tr>
<tr>
<td>Boulton, A.J.M.</td>
<td>183-187</td>
</tr>
<tr>
<td>Broughton Pipkin, F.</td>
<td>499-505</td>
</tr>
<tr>
<td>Burnett, J.C.</td>
<td>357-362</td>
</tr>
<tr>
<td>Buxton, B.F.</td>
<td>91-96</td>
</tr>
<tr>
<td>Cabili, S.</td>
<td>379-384</td>
</tr>
<tr>
<td>Cacabelos, R.</td>
<td>153-156</td>
</tr>
<tr>
<td>Calcitai, A.</td>
<td>345-355</td>
</tr>
<tr>
<td>Capdevila, A.</td>
<td>81-85</td>
</tr>
<tr>
<td>Carr, P.</td>
<td>507-510</td>
</tr>
<tr>
<td>Chan, S.-H.</td>
<td>127-133</td>
</tr>
<tr>
<td>Chang, C.-J.</td>
<td>127-133</td>
</tr>
<tr>
<td>Chen, J.R.</td>
<td>91-96</td>
</tr>
<tr>
<td>Cheng, C.</td>
<td>97-103</td>
</tr>
<tr>
<td>Chow, N.-H.</td>
<td>127-133</td>
</tr>
<tr>
<td>Christensen, N.J.</td>
<td>269-276</td>
</tr>
<tr>
<td>Clark, A.F.</td>
<td>435-446</td>
</tr>
<tr>
<td>Clark, M.L.</td>
<td>409-415</td>
</tr>
<tr>
<td>Coats, A.J.S.</td>
<td>345-355</td>
</tr>
<tr>
<td>Collins, K.J.</td>
<td>485-492</td>
</tr>
<tr>
<td>Coote, J.H.</td>
<td>235-241</td>
</tr>
<tr>
<td>Coppack, S.W.</td>
<td>409-415</td>
</tr>
<tr>
<td>Corry, D.B.</td>
<td>2-8</td>
</tr>
<tr>
<td>Court-Payen, M.</td>
<td>269-276</td>
</tr>
<tr>
<td>Cowley, A.J.</td>
<td>473-483</td>
</tr>
<tr>
<td>Csernhovskv, T.</td>
<td>379-384</td>
</tr>
<tr>
<td>Davenport, A.P.</td>
<td>37-46</td>
</tr>
<tr>
<td>De Backer, D.</td>
<td>105-111</td>
</tr>
<tr>
<td>De Blaauw, I.</td>
<td>457-466</td>
</tr>
<tr>
<td>De Jong, P.E.</td>
<td>393-401</td>
</tr>
<tr>
<td>De Landázuri, M.O.</td>
<td>148-153</td>
</tr>
<tr>
<td>De Zeeuw, D.</td>
<td>393-401</td>
</tr>
<tr>
<td>Deutz, N.E.P.</td>
<td>457-466</td>
</tr>
<tr>
<td>Devynck, M.-A.</td>
<td>403-407</td>
</tr>
<tr>
<td>Diez, J.J.</td>
<td>169-171</td>
</tr>
<tr>
<td>Dodd, C.M.</td>
<td>417-425</td>
</tr>
<tr>
<td>Donnelly, A.E.</td>
<td>119-125</td>
</tr>
<tr>
<td>Doré, C.J.</td>
<td>485-492</td>
</tr>
<tr>
<td>Douglas, J.T.</td>
<td>183-187</td>
</tr>
<tr>
<td>Drake-Holland, A.J.</td>
<td>363-368</td>
</tr>
<tr>
<td>Easton, J.C.</td>
<td>485-492</td>
</tr>
<tr>
<td>Eaton, S.</td>
<td>307-313</td>
</tr>
<tr>
<td>Edwards, R.H.T.</td>
<td>295-300, 467-472</td>
</tr>
<tr>
<td>Egido, J.</td>
<td>161-162</td>
</tr>
<tr>
<td>Ellis, C.C.</td>
<td>2-8</td>
</tr>
<tr>
<td>Evans, T.W.</td>
<td>47-54, 173-182, 301-306</td>
</tr>
<tr>
<td>Fahal, I.</td>
<td>295-300</td>
</tr>
<tr>
<td>Färkkilä, M.A.</td>
<td>315-319</td>
</tr>
<tr>
<td>Feihl, F.</td>
<td>369-377</td>
</tr>
<tr>
<td>Fisher, R.M.</td>
<td>409-415</td>
</tr>
<tr>
<td>Fleisher, L.A.</td>
<td>97-103</td>
</tr>
<tr>
<td>Floras, J.S.</td>
<td>189-195</td>
</tr>
<tr>
<td>Fogh-Andersen, N.</td>
<td>511-515</td>
</tr>
<tr>
<td>Ford, G.A.</td>
<td>493-497</td>
</tr>
<tr>
<td>Forskins, A.S.</td>
<td>235-241</td>
</tr>
<tr>
<td>Forni, L.G.</td>
<td>507-510</td>
</tr>
<tr>
<td>Frank, S.M.</td>
<td>97-103</td>
</tr>
<tr>
<td>Frayn, K.N.</td>
<td>243-253, 409-415, 453-456</td>
</tr>
<tr>
<td>Fuller, B.J.</td>
<td>135-141</td>
</tr>
<tr>
<td>Garrard, C.S.</td>
<td>345-355</td>
</tr>
<tr>
<td>Garrido, E.</td>
<td>81-85</td>
</tr>
<tr>
<td>Georgiannos, S.N.</td>
<td>73-75</td>
</tr>
<tr>
<td>Ghalay, A.</td>
<td>417-425</td>
</tr>
<tr>
<td>Giles, S.L.</td>
<td>453-456</td>
</tr>
<tr>
<td>Goka, J.</td>
<td>77-80</td>
</tr>
<tr>
<td>Goldstein, D.S.</td>
<td>337-343</td>
</tr>
<tr>
<td>González-Pan, A.</td>
<td>169-171</td>
</tr>
<tr>
<td>Gorodetsky, E.</td>
<td>287-293</td>
</tr>
<tr>
<td>Gosling, R.G.</td>
<td>143-144, 433-434</td>
</tr>
<tr>
<td>Green, C.J.</td>
<td>135-141</td>
</tr>
<tr>
<td>Griffiths, M.J.D.</td>
<td>47-54</td>
</tr>
<tr>
<td>Gutteridge, J.M.C.</td>
<td>47-54</td>
</tr>
<tr>
<td>Halliday, D.</td>
<td>73-75</td>
</tr>
<tr>
<td>Hamada, M.</td>
<td>197-204</td>
</tr>
<tr>
<td>Hannedouche, T.P.</td>
<td>205-213</td>
</tr>
<tr>
<td>Heigenhauser, G.J.F.</td>
<td>323-335</td>
</tr>
<tr>
<td>Heigher, J.</td>
<td>385-391</td>
</tr>
<tr>
<td>Hellie, J.R.</td>
<td>467-472</td>
</tr>
<tr>
<td>Herrero, J.I.</td>
<td>162-167</td>
</tr>
<tr>
<td>Hidalgo, M.A.</td>
<td>135-141</td>
</tr>
<tr>
<td>Higgs, C.M.B.</td>
<td>227-234</td>
</tr>
<tr>
<td>Hilton, P.J.</td>
<td>507-510</td>
</tr>
<tr>
<td>Hiwada, K.</td>
<td>197-204</td>
</tr>
<tr>
<td>Hopkins, K.D.</td>
<td>143-144, 433-434</td>
</tr>
<tr>
<td>Horacek, V.</td>
<td>385-391</td>
</tr>
<tr>
<td>Hest, U.</td>
<td>269-276</td>
</tr>
<tr>
<td>Hughes, R.D.</td>
<td>77-80</td>
</tr>
<tr>
<td>Humphreys, S.M.</td>
<td>409-415</td>
</tr>
<tr>
<td>Hurni, J.-M.</td>
<td>369-377</td>
</tr>
<tr>
<td>Hynd, J.W.</td>
<td>363-368</td>
</tr>
<tr>
<td>Iaina, A.</td>
<td>379-384</td>
</tr>
<tr>
<td>Imai, Y.</td>
<td>55-60</td>
</tr>
<tr>
<td>Ishizaki, T.</td>
<td>517-523</td>
</tr>
<tr>
<td>Ison, J.</td>
<td>485-492</td>
</tr>
<tr>
<td>Jaap, A.J.</td>
<td>113-117</td>
</tr>
<tr>
<td>Jackson, A.A.</td>
<td>215-225</td>
</tr>
<tr>
<td>Jackson, M.J.</td>
<td>295-300, 467-472</td>
</tr>
<tr>
<td>Jacobs, M.-C.</td>
<td>337-343</td>
</tr>
<tr>
<td>Javiera, C.</td>
<td>81-85</td>
</tr>
<tr>
<td>Jobanputra, P.</td>
<td>61-71</td>
</tr>
<tr>
<td>Johnson, I.R.</td>
<td>499-505</td>
</tr>
<tr>
<td>Johnston, C.I.</td>
<td>31-36</td>
</tr>
<tr>
<td>Jones, N.L.</td>
<td>323-335</td>
</tr>
</tbody>
</table>
Kairemo, K.J. 315-319  
Kalman, R. 287-293  
Kanazawa, M. 31-36  
Kasai, Y. 55-60  
Kato, J. 55-60  
Kawakami, H. 197-204  
Keane, H.M. 77-80  
Kearney, M.T. 473-483  
Kelbaek, H. 269-276  
Kinosita, M. 357-362  
Kishi, Y. 517-523  
Kohzuki, M. 31-36  
Kok, W.E.M. 144-146  
Kramer, H.J. 385-391  
Kuc, R.E. 37-46  
Lacour, B. 205-213  
Laszlo, G. 227-234  
Lehmann, E.D. 143-144, 433-434  
Lenders, J.W.M. 337-343  
Leyssac, P.P. 511-515  
Liaudet, L. 369-377  
Liderth, S.A. 183-187  
Lin, J.S.-N. 127-133  
Liu, J.J. 91-96  
Liu, S.F. 301-306  
Logan, A.G. 189-195  
Lorente, L. 321-322  
Lorenzen, T. 269-276  
Macdonald, I.A. 473-483  
MacLennan, P.A. 467-472  
Mahdy, Z.A. 493-497  
Mann, D.J. 135-141  
Maree, A. 379-384  
Markert, M. 369-377  
Martinez, F. 205-213  
Mato, J.M. 147-148  
Matsuda, Y. 357-362  
Matsukawa, T. 97-103  
Mc Ardle, A. 295-300, 467-472  
Mc Ardle, F. 295-300  
Meakin, T.S. 215-225  
Melot, C. 105-111  
Messent, M. 47-54  
Miettinen, T.A. 315-319  
Millanvoye-Van Brussel, E. 403-407  
Miller, J.A. 189-195  
Miyabo, S. 517-523  
Mohan, R. 255-260  
Montserrat, E. 167-169  
Moraine, J.J. 105-111  
Mullins, J.J. 435-446  
Munakata, M. 55-60  
Nakai, T. 517-523  
Natov, S. 205-213  
Navarro-Lopez, F. 156-158  
Navis, G. 393-401  
Neusser, M. 9-12  
Newton, R. 301-306  
Nielsen, C.B. 87-89  
Nishiyama, A. 55-60  
Noble, M.I.M. 363-368  
Nuki, G. 61-71  
O'Reilly, G. 37-46  
Ohkubo, T. 55-60  
Okayama, H. 197-204  
Olsen, N.V. 511-515  
Onodera, N. 55-60  
Page, S.F. 295-300  
Pedersen, E.B. 87-89  
Pedersen-Bjergaard, U. 269-276  
Perry, A.J. 473-483  
Peters, R.J.G. 144-146  
Peters, N.S. 447-452  
Plumpton, C. 37-46  
Pinto, J. 162-167  
Pujol, J. 81-85  
Quinlan, G.J. 47-54  
Raa sch, R.H. 427-431  
Radaelli, A. 345-355  
Rahemtulla, F. 747-425  
Rasmussen, H. 269-276  
Ravell, C.L. 453-456  
Record, C.O. 307-313  
Reeder, M. 345-355  
Robson, S.C. 493-497  
Rodriguez-Arnao, J. 169-171  
Rossie, T. 369-377  
Roszman, C. 167-169  
Ruijlope, L.M. 159-160  
Ruocco, N.A. 261-268  
Sacco, P. 485-492  
Sair, M. 173-182  
Salter, D.M. 61-71  
Samra, J.S. 453-456  
Sasaki, F. 517-523  
Sato, T. 31-36  
Satoh, H. 55-60  
Saxton, J.M. 119-125  
Schmitt, F. 205-213  
Scott, P.G. 417-425  
Scullard, T.F. 277-285  
Segura, R. 81-85  
Sekino, M. 55-60  
Sessler, D.I. 97-103  
Shanmugasundaram, K.R. 255-260  
Sharp, M.G.F. 435-446  
Sheron, N. 77-80  
Shore, A.C. 113-117  
Silverberg, D.S. 379-384  
Sipkema, P. 144-146  
Skorecki, K.L. 189-195  
Sleight, P. 345-355  
Smits, P. 337-343  
Solda, P.L. 345-355  
Strandberg, T.A. 315-319  
Strandgaard, S. 511-515  
Streeten, D.H.P. 277-285  
Stubbs, T.A. 473-483  
Sundaram, R.K. 255-260  
Supaporn, T. 357-362  
Taavitsainen, M.J. 315-319  
Tepel, M. 9-12  
Thien, T. 337-343  
Thurston, H. 21-29  
Tooke, J.E. 113-117  
Townend, J.N. 235-241  
Treacher, D.F. 507-510  
Tredget, E.E. 417-425  
Tsuji, I. 55-60  
Tsutsuini, E. 31-36  
Tuck, M.L. 2-8  
Tzai, T.-S. 127-133  
Ulshen, M.H. 427-431  
Van Goor, H. 393-401  
Vanfraechem, J. 105-111  
Vannier, C.A. 97-103  
Vejera, J.J. 81-85  
Veves, A. 183-187  
Vijayalingam, S. 255-260  
Vincent, J.-L. 105-111  
Von Meyenfeldt, M.F. 457-466  
Wapstra, F.H. 393-401  
Watanabe, N. 55-60  
Wei, C.-M. 357-362  
Weinstock, M. 287-293  
Wennberg, P.W. 357-362
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
<th>Author</th>
<th>Pages</th>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willemsen, J.J.</td>
<td>337-343</td>
<td>Yasujima, M.</td>
<td>31-36</td>
<td>Zaidi, K.F.</td>
<td>13-19</td>
</tr>
<tr>
<td>Williams, C.M.</td>
<td>243-253</td>
<td>Yeh, T.-M.</td>
<td>127-133</td>
<td>Zaitoun, A.M.</td>
<td>307-313</td>
</tr>
<tr>
<td>Williams, R.</td>
<td>77-80</td>
<td>Yoshida, K.</td>
<td>31-36</td>
<td>Zhu, Z.</td>
<td>9-12</td>
</tr>
<tr>
<td>Winlove, C.P.</td>
<td>173-182</td>
<td>Yoshino, H.</td>
<td>55-60</td>
<td>Zidek, W.</td>
<td>9-12</td>
</tr>
<tr>
<td>Wollman, Y.</td>
<td>379-384</td>
<td>Young, M.J.</td>
<td>183-187</td>
<td>Zinman, B.</td>
<td>189-195</td>
</tr>
<tr>
<td>Wright, D.A.</td>
<td>507-510</td>
<td>Yu, T.-K.</td>
<td>261-268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wright, M.</td>
<td>61-71</td>
<td>Yudkin, J.S.</td>
<td>13-19</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acetylcholine
   Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
Acid-base control
   muscle, exercise 323–335*
Acute tobacco smoking
   probucol 517–523
Acute renal failure
   lactate metabolism, haemofiltration 507–510
Adipose tissue
   carbohydrate metabolism, insulin resistance 409–415
   interstitial glycerol 453–456
Adrenaline
   baroreflex activity, lower body negative pressure 337–343
Adrenergic agents
   oxygen consumption/delivery relationship 105–111
Adriamycin
   angiotensin-converting enzyme inhibition, proteinuria 393–401
Ageing
   facial cooling, cardiorespiratory reflexes 485–492
Alcohol
   fatty liver, β-oxidation 307–313
Altitude
   brain damage, Sherpas 81–85
Amino acid turnover
   muscle, starvation 457–466
Ammonia
   protein turnover, bed rest 73–75
Angiogenesis
   basic fibroblast growth factor, urothelial carcinoma 127–133
   Angiotensin I-receptor blockade renal effects 205–213
   Angiotensin receptors myometrium, pregnancy 499–505
Angiotensin-converting enzyme inhibitors
   resistance artery, endothelium-dependent relaxation 21–29
Angiotensin-converting enzyme inhibition nephrosis, proteinuria 393–401
   renal effects 205–213
Antioxidant enzymes
   lipid peroxidation, diabetes 255–260
Antioxidant vitamins
   lipid peroxidation, diabetes 255–260
L-Arginine
   nitric oxide, diabetes mellitus 379–384
Arrhythmias
   gap junctions, myocardium 447–452
Arteries
   endothelin B receptor agonists and antagonists 91–96
Articular cartilage
   membrane potential, ion channels 61–71
Asthma
   perception, treatment 227–234
Atrial natriuretic peptide
   gene expression, renovascular hypertension 197–204
   heart failure, diuretics 31–36
   mean blood pressure, epoprostenol 87–89
Autonomic insufficiency
   orthostatic intolerance, venous pooling 277–285
Autonomic tone
   skin microcirculation 345–355
Baroreflex activity
   catecholamines, lower body negative pressure 337–343
   skin microcirculation 345–355
Baroreflex sensitivity
   renal nerves, hypertension 287–293
Basic fibroblast growth factor
   inflammation, urothelial carcinoma 127–133
Subject Index

Beclomethasone
asthma, perception 227–234
Bed rest
protein turnover, urea 73–75
Big endothelin
immunochemistry, human endocardial endothelial cells 37–46
Bile acid malabsorption
lathosterol, 73SeHCAT test 315–319
Blood
carbon dioxide, exercise 323–335*
Blood flow
autonomic tone, skin 345–355
meal composition 269–276
Blood pressure
lisinopril, angiotensin-converting enzyme inhibition 393–401
seasonal variation 55–60
Blood pressure regulation
gene targeting 435–446*
Bradykinin
Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
Brain damage
Sherpas, magnetic resonance 81–85
Brain natriuretic peptide
gene expression, renovascular hypertension 197–204
Breath-holding
facial cooling, ageing 485–492
Bronchoconstriction
perception, treatment 227–234
Buffering capacity
platelets, diabetes 13–19
Burns
wound healing, proteoglycans 417–425
Calcium
vascular smooth muscle, ouabain 9–12
L-Canavanine
nitric oxide synthase, endotoxaemia 369–377
Canine kidney
glomerular haemodynamics, endothelin-1 385–391
Capillary filtration coefficient
diabetes, microangiopathy 113–117
Carbohydrate
postprandial haemodynamics 269–276
Carbohydrate meal
haemodynamics, cardiac transplant 473–483
Carbohydrate metabolism
insulin resistance 409–415
Carbon dioxide
metabolism, exercise 323–335*
Cardiac output
meal composition 269–276
Cardiac transplant
postprandial haemodynamics 473–483
Cardiac vagus
facial cooling, ageing 485–492
Cardiology
Spain 156–158
Cardiomyocytes
phospholipase A2, hypertension 403–407
Cardiopulmonary baroreceptors
catecholamines, lower body negative pressure 337–343
Cardiorespiratory reflexes
facial cooling, ageing 485–492
Cartilage
membrane potential, ion channels 61–71
Catecholamines
baroreflex activity, lower body negative pressure 337–343
Cell attachment
endothelial cells, organ preservation 135–141
Cerebral hypoxia
Sherpas, magnetic resonance 81–85
Chlorothiazide
renin, heart failure 31–36
Cholesterol
coronary vascular reserve, endothelium 261–268
Cholesterol synthesis
bile acid synthesis, lathosterol 315–319
Chondrocytes
mechanoreceptors, ion channels 61–71
Chronic fatigue syndrome
enterovirus, polymerase chain reaction 295–300
Chronic renal failure
sodium, potassium pump 3–8
Climbing
brain damage, Sherpas 81–85
Clinical research
progress in Spain 147–171
Coagulation
thrombin, recombinant hirudin 363–368
Compliance
definitions 143–146, 433–434
Connexin43
arrhythmias, gap junctions 447–452
Coronary blood flow
natriuretic peptides 357–362
Coronary heart disease
fatty acids 243–253*
Coronary thrombosis
thrombin, recombinant hirudin 363–368
Coronary vascular reserve
endothelium, hypercholesterolaemia 261–268
Creatine kinase  
muscle damage, chronic fatigue syndrome 295–300

Cromoglycate  
asthma, perception 227–234

Cyclo-oxygenase  
gene expression, endotoxaemia 301–306

Cytokines  
fulminant hepatic failure 77–80

Daytime length  
blood pressure 55–60

Definitions  
compliance 433–434

Dermatan sulphate  
burns, wound healing 417–425

Diabetes  
antioxidant status, lipid peroxidation 255–260
fatty acids, coronary heart disease 243–253*
microalbuminuria, sodium/hydrogen exchange rate 13–19
microangiopathy, vascular permeability 113–117
nitric oxide, l-arginine 379–384
peripheral neuropathy, rheology 183–187
plasma renin activity, hyperglycaemia 189–195

Diuretics  
renin, heart failure 31–36

Dobutamine  
oxygen consumption/delivery relationship 105–111

Dopamine  
renal tubular function, lithium clearance 511–515

Doxorubicin  
angiotensin-converting enzyme inhibition, 
proteinuria 393–401

Eating  
haemodynamic effects 269–276

Eccentric exercise  
strength loss, muscle damage 119–125

Elastase inhibitory capacity  
acute tobacco smoking, probucol 517–523

Embryonic stem cells  
gene targeting 435–446*

Endocardial endothelial cells  
endothelin, reverse transcriptase–polymerase chain reaction 37–46

Endocrinology  
Spain 169–171

Endogenous lithium clearance  
dopamine, renal tubular function 511–515

Endogenous natriuretic peptides  
coronary blood flow 357–362

Endothelial cells  
permeability, organ preservation 135–141

Endothelin  
reverse transcriptase–polymerase chain reaction, human endocardial endothelial cells 37–46

Endothelin B receptor agonists  
arteries 91–96

Endothelin B receptor antagonists  
arteries 91–96

Endothelin receptor subtypes  
arteries 91–96

Endothelin-1  
glomerular haemodynamics 385–391

Endothelium  
coronary vascular reserve, hypercholesterolaemia 261–268

Endothelium-dependent relaxation  
Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29

Endotoxaemia  
cyclo-oxygenase, gene expression 301–306
nitric oxide synthase, L-canavanine 369–377

Enterovirus  
chronic fatigue syndrome, polymerase chain reaction 295–300

Epidermal growth factor  
mucosal mass, starvation 427–431

Epoprostenol  
atrial natriuretic peptide, mean blood pressure 87–89

Exercise  
carbon dioxide, metabolism 323–335*
protein turnover, bed rest 73–75

Exogenous lithium clearance  
dopamine, renal tubular function 511–515

Facial cooling  
cardiorespiratory reflexes, ageing 485–492

Faecal bile acid excretion  
lathosterol, $^{75}$SeHCAT test 315–319

Fasting  
muscle necrosis, mdx mouse 467–472

Fat  
postprandial haemodynamics 269–276

Fat meal  
haemodynamics, cardiac transplant 473–483

Fatty acids  
coronary heart disease 243–253*

Ferroxidase activity  
acute tobacco smoking, probucol 517–523

Forearm  
carbohydrate metabolism, insulin resistance 409–415

Forearm blood flow  
hyperglycaemia, diabetes 189–195
Fractional dextran clearance
  renin–angiotensin system inhibition 205–213
Fulminant hepatic failure
tumour necrosis factor soluble receptor 77–80

Gap junctions
  arrhythmias, myocardium 447–452
Gene expression
cyclo-oxygenase, endotoxaemia 301–306
  natriuretic peptides, renovascular hypertension 197–204
Gene targeting
  blood pressure regulation 435–446*
Genetic hypertension
  phospholipase A₂, cardiomyocytes 403–407
Glomerular filtration rate
  hyperglycaemia, diabetes 189–195
  renin–angiotensin system inhibition 205–213
Glomerular haemodynamics
  endothealin-1 385–391
Glomerular ultrafiltration
  endothealin-1 385–391
Glomerulosclerosis
  angiotensin-converting enzyme inhibition 393–401
Glucose uptake
  insulin resistance 409–415
Glutathione
  acute tobacco smoking, probucol 517–523
Glycerol
  muscle, adipose tissue 453–456
Glycine
  protein turnover, bed rest 73–75
Guanylyl cyclase
  endogenous natriuretic peptides 357–362

Haematology
  Spain 167–169
Haemodynamic effects
  meal composition 269–276
Haemofiltration
  lactate metabolism, acute renal failure 507–510
Heart failure
  renin, diuretics 31–36
  vascular endothelium, psycho-neuro-immune–endocrine system 321–322
Heart rate
  atrial natriuretic peptide, epoprostenol 87–89
Heart rate variability
  respiratory sinus arrhythmia 227–234
  skin microcirculation, autonomic tone 345–355
  spectral analysis, thermoregulation 97–103
Hepatology
  Spain 162–167

Hirudin
  thrombin, intracoronary thrombosis 363–368
Homologous recombination
  gene targeting 435–446*
Host–tumour interaction
  basic fibroblast growth factor, urothelial carcinoma 127–133
Hypercholesterolaemia
  coronary vascular reserve, endothelium 261–268
Hyperglycaemia
  plasma renin activity, diabetes 189–195
Hypertension
  baroreflex sensitivity, renal nerves 287–293
  phospholipase A₂, cardiomyocytes 403–407
  resistance artery, angiotensin-converting enzyme inhibitors 21–29
  sodium/hydrogen exchange rate, diabetes 13–19
  Spain 159–160
Hypertension research
  gene targeting 435–446*
Hypertrophic scars
  wound healing, proteoglycans 417–425
Hypertrophy
  arrhythmias, gap junctions 447–452
Hypothermia
  heart rate variability, spectral analysis 97–103
Hypoxia
  Sherpas, magnetic resonance 81–85
Hypoxic pulmonary vasoconstriction
  lung oedema, reactive oxygen species scavengers 47–54

Ileal resection
  bile acid malabsorption 315–319
Immunological research
  Spain 148–153
Indoor temperature
  blood pressure 55–60
Inducible nitric oxide synthase
  endotoxaemia, L-canavanine 369–377
Inflammation
  basic fibroblast growth factor, urothelial carcinoma 127–133
Infra-red photoplethysmography
  skin microcirculation, autonomic tone 345–355
Insulin resistance
  carbohydrate metabolism 409–415
  fatty acids, coronary heart disease 243–253*
Interstitial glycerol
  muscle, adipose tissue 453–456
Ischaemia
  arrhythmias, gap junctions 447–452
Ischaemia–reperfusion injury
  hypoxic pulmonary vasoconstriction, reactive oxygen species scavengers 47–54
<table>
<thead>
<tr>
<th>Subject</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney function</td>
<td>511–515</td>
</tr>
<tr>
<td>dopamine, lithium clearance</td>
<td></td>
</tr>
<tr>
<td>Lactate metabolism</td>
<td>507–510</td>
</tr>
<tr>
<td>haemofiltration, acute renal failure</td>
<td></td>
</tr>
<tr>
<td>insulin resistance</td>
<td>409–415</td>
</tr>
<tr>
<td>Lactic acidosis</td>
<td>507–510</td>
</tr>
<tr>
<td>haemofiltration, acute renal failure</td>
<td></td>
</tr>
<tr>
<td>Lathosterol</td>
<td></td>
</tr>
<tr>
<td>&quot;75SeHCAT test, bile acid malabsorption</td>
<td>315–319</td>
</tr>
<tr>
<td>Lipid peroxide</td>
<td>517–523</td>
</tr>
<tr>
<td>acute tobacco smoking, probucol</td>
<td></td>
</tr>
<tr>
<td>Lipid peroxidation</td>
<td>255–260</td>
</tr>
<tr>
<td>antioxidant status, diabetes</td>
<td></td>
</tr>
<tr>
<td>Lipolysis</td>
<td>453–456</td>
</tr>
<tr>
<td>adipose tissue</td>
<td></td>
</tr>
<tr>
<td>Lipopolysaccharide</td>
<td>301–306</td>
</tr>
<tr>
<td>cyclo-oxygenase, gene expression</td>
<td></td>
</tr>
<tr>
<td>Lisinopril</td>
<td>393–401</td>
</tr>
<tr>
<td>angiotensin-converting enzyme inhibition, nephrosis</td>
<td></td>
</tr>
<tr>
<td>Lithium clearance</td>
<td>511–515</td>
</tr>
<tr>
<td>dopamine, renal tubular function</td>
<td></td>
</tr>
<tr>
<td>renin–angiotensin system inhibition</td>
<td>205–213</td>
</tr>
<tr>
<td>Liver</td>
<td>307–313</td>
</tr>
<tr>
<td>alcohol, β-oxidation</td>
<td></td>
</tr>
<tr>
<td>Liver failure</td>
<td>77–80</td>
</tr>
<tr>
<td>tumour necrosis factor soluble receptor</td>
<td></td>
</tr>
<tr>
<td>Lower body negative pressure</td>
<td>337–343</td>
</tr>
<tr>
<td>baroreflex activity, catecholamines</td>
<td></td>
</tr>
<tr>
<td>facial cooling, ageing</td>
<td>485–492</td>
</tr>
<tr>
<td>Luminal epidermal growth factor</td>
<td>427–431</td>
</tr>
<tr>
<td>mucosal mass, starvation</td>
<td></td>
</tr>
<tr>
<td>Lung oedema</td>
<td>47–54</td>
</tr>
<tr>
<td>hypoxic pulmonary vasoconstriction, reactive oxygen species scavengers</td>
<td></td>
</tr>
<tr>
<td>Mature scars</td>
<td>417–425</td>
</tr>
<tr>
<td>wound healing, proteoglycans</td>
<td></td>
</tr>
<tr>
<td>Mdx mouse</td>
<td>467–472</td>
</tr>
<tr>
<td>muscle necrosis, fasting</td>
<td></td>
</tr>
<tr>
<td>Meal composition</td>
<td>269–276</td>
</tr>
<tr>
<td>haemodynamic effects</td>
<td></td>
</tr>
<tr>
<td>Mean blood pressure</td>
<td>87–89</td>
</tr>
<tr>
<td>atrial natriuretic peptide, epoprostenol</td>
<td></td>
</tr>
<tr>
<td>Membrane transport</td>
<td>457–466</td>
</tr>
<tr>
<td>amino acids, starvation</td>
<td></td>
</tr>
<tr>
<td>Menstrual cycle</td>
<td>499–505</td>
</tr>
<tr>
<td>angiotensin receptors, myometrium</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>323–335*</td>
</tr>
<tr>
<td>carbon dioxide, exercise</td>
<td></td>
</tr>
<tr>
<td>Microalbuminurina</td>
<td>113–117</td>
</tr>
<tr>
<td>diabetes, vascular permeability</td>
<td></td>
</tr>
<tr>
<td>sodium/hydrogen exchange rate, diabetes</td>
<td>13–19</td>
</tr>
<tr>
<td>Microangiopathy</td>
<td>113–117</td>
</tr>
<tr>
<td>diabetes, vascular permeability</td>
<td></td>
</tr>
<tr>
<td>Microcirculation</td>
<td>173–182*</td>
</tr>
<tr>
<td>sepsis</td>
<td></td>
</tr>
<tr>
<td>Microvascular disease</td>
<td>183–187</td>
</tr>
<tr>
<td>rheology, peripheral neuropathy</td>
<td></td>
</tr>
<tr>
<td>Mitochondria</td>
<td>295–300</td>
</tr>
<tr>
<td>muscle, chronic fatigue syndrome</td>
<td></td>
</tr>
<tr>
<td>Monolayer continuity</td>
<td>135–141</td>
</tr>
<tr>
<td>endothelial cells, organ preservation</td>
<td></td>
</tr>
<tr>
<td>N\textsuperscript{G}monomethyl-L-arginine</td>
<td>493–497</td>
</tr>
<tr>
<td>pregnancy</td>
<td></td>
</tr>
<tr>
<td>Mouse embryonic stem cells</td>
<td>435–446*</td>
</tr>
<tr>
<td>gene targeting</td>
<td></td>
</tr>
<tr>
<td>Mucosal mass</td>
<td>427–431</td>
</tr>
<tr>
<td>epidermal growth factor, starvation</td>
<td></td>
</tr>
<tr>
<td>Muscle pain</td>
<td>295–300</td>
</tr>
<tr>
<td>virus infection, chronic fatigue syndrome</td>
<td></td>
</tr>
<tr>
<td>Muscle necrosis</td>
<td>119–125</td>
</tr>
<tr>
<td>strength loss, eccentric exercise</td>
<td></td>
</tr>
<tr>
<td>Muscle damage</td>
<td>467–472</td>
</tr>
<tr>
<td>fasting, mdx mouse</td>
<td></td>
</tr>
<tr>
<td>Muscular dystrophy</td>
<td>467–472</td>
</tr>
<tr>
<td>fasting, mdx mouse</td>
<td></td>
</tr>
<tr>
<td>Myocardium</td>
<td>447–452</td>
</tr>
<tr>
<td>arrhythmias, gap junctions</td>
<td></td>
</tr>
<tr>
<td>Myometrium</td>
<td>499–505</td>
</tr>
<tr>
<td>angiotensin receptors, pregnancy</td>
<td></td>
</tr>
<tr>
<td>Natriuretic peptides</td>
<td>197–204</td>
</tr>
<tr>
<td>gene expression, renovascular hypertension</td>
<td></td>
</tr>
<tr>
<td>Natriuretic peptide receptor antagonist</td>
<td>357–362</td>
</tr>
<tr>
<td>coronary blood flow</td>
<td></td>
</tr>
<tr>
<td>Necrosis</td>
<td>467–472</td>
</tr>
<tr>
<td>fasting, mdx mouse</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>161–162</td>
</tr>
<tr>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Nephrosis</td>
<td>379–384</td>
</tr>
<tr>
<td>angiotensin-converting enzyme inhibition, proteinuria</td>
<td>393–401</td>
</tr>
<tr>
<td>Neuroscience</td>
<td>153–156</td>
</tr>
<tr>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Nitrate</td>
<td>379–384</td>
</tr>
<tr>
<td>diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td>Nitric oxide</td>
<td>493–497</td>
</tr>
<tr>
<td>L-arginine, diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td>pregnancy</td>
<td></td>
</tr>
</tbody>
</table>
Nitric oxide synthase
endotoxaemia, L-canavanine 369-377
gene expression, endotoxaemia 301-306
Nitric oxide synthase inhibitor
diabetes mellitus 379-384
Nitrite
diabetes mellitus 379-384
Nitroprusside
oxygen consumption/delivery relationship 105-111
Non-essential nitrogen
protein requirements 215-225
Non-esterified fatty acids
coronary heart disease 243-253*
Noradrenaline
baroreflex activity, lower body negative pressure 337-343
Obesity
fatty acids, coronary heart disease 243-253*
Organ preservation
endothelial cells, permeability 135-141
Orthostatic hypotension
autonomic insufficiency, venous pooling 277-285
Orthostatic tachycardia
autonomic insufficiency, venous pooling 277-285
β-Oxidation
fatty liver, alcohol 307-313
Ouabain
calcium, vascular smooth muscle 9-12
Outdoor temperature
blood pressure 55-60
Oxygen uptake
dobutamine, nitroprusside 105-111
Peak expiratory flow
asthma, perception 227-234
Perception
asthma, treatment 227-234
Peripheral neuropathy
rheological and microvascular parameters 183-187
Permeability
endothelial cells, organ preservation 135-141
Phenylalanine turnover
muscle, starvation 457-466
Phospholipase A₁,
cardiomyocytes, hypertension 403-407
Physicochemical factors
carbon dioxide, exercise 323-335*
Plasma renin activity
hyperglycaemia, diabetes 189-195
renal nerves, hypertension 287-293
Platelets
recombinant hirudin, intracoronary thrombosis 363-368
sodium/hydrogen exchange rate, diabetes 13-19
Policy on clinical research
Spain 147-148
Polymerase chain reaction
enterovirus, chronic fatigue syndrome 295-300
Postprandial haemodynamics
heart failure 321-322
Postprandial metabolism
insulin resistance 409-415
Posture
sympathetic activity 345-355
Power spectrum
skin microcirculation, autonomic tone 345-355
Pregnancy
angiotensin receptors, myometrium 499-505
nitric oxide 493-497
Probucol
acute tobacco smoking 517-523
Prostacyclin
atrial natriuretic peptide, mean blood pressure 87-89
Prostaglandin G/H synthase
gene expression, endotoxaemia 301-306
Protein
postprandial haemodynamics 269-276
Protein requirements
urea kinetics 215-225
Protein turnover
muscle, starvation 457-466
post-absorptive state, bed rest 73-75
Proteinuria
angiotensin-converting enzyme inhibition, nephrosis 393-401
Proteoglycans
burns, wound healing 417-425
Psycho-neuro-immune-endocrine system
vascular endothelium, heart failure 321-322
Reactive oxygen species scavengers
lung oedema, hypoxic pulmonary vasoconstriction 47-54
Renal haemodynamics
endothelin-1 385-391
Renal nerves
baroreflex sensitivity, hypertension 287-293
Renal tubular function
dopamine, lithium clearance 511-515
Renovascular hypertension
natriuretic peptides, gene expression 197-204
Resistance artery
Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
Respiratory sinus arrhythmia
heart rate variability 227–234
Rheology
microvascular disease, peripheral neuropathy 183–187

Salt intake
renal nerves, hypertension 287–293
Scopolamine
respiratory sinus arrhythmia 227–234
Seasonal variation
blood pressure 55–60
$^{75}$SeHCAT test
lathosterol, bile acid malabsorption 315–319
Sepsis
cyclo-oxygenase, endotoxaemia 301–306
microcirculation 173–182*
Sherpas
cerebral hypoxia, magnetic resonance 81–85
Skin microcirculation
autonomic tone 345–355
Small intestine
epidermal growth factor, starvation 427–431
Sodium excretion
renal nerves, hypertension 287–293
Sodium/hydrogen exchange rate
diabetes, microalbuminura 13–19
Sodium–potassium–chloride co-transport
uraemia 3–8
Sodium, potassium pump
uraemia 3–8
Spain
progress in clinical research 147–171
Spectral analysis
heart rate variability, thermoregulation 97–103
Starvation
amino acid turnover, protein turnover 457–466
mucosal mass, epidermal growth
factor 427–431
Steatosis
alcohol, β-oxidation 307–313
Strength loss
muscle damage, eccentric exercise 119–125
Streptozotocin
diabetes mellitus, nitric oxide 379–384
Stress
fatty acids, coronary heart disease 243–253*
Superoxide dismutase
lung oedema, hypoxic pulmonary vasoconstriction 47–54
Sympathetic nerves
sodium retention, hypertension 287–293

Temperature
blood pressure 55–60
Theophylline
asthma, perception 227–234
Thermoregulation
heart rate variability, spectral analysis 97–103
Thrombin
recombinant hirudin, intracoronary thrombosis 363–368
Thrombosis
thrombin, recombinant hirudin 363–368
Tissue nutrition
sepsis 173–182*
Tobacco smoke inhalation
probucol 517–523
Tocopherol
acute tobacco smoking, probucol 517–523
Total exchangeable body sodium
heart failure, diuretics 31–36
Tracer
protein turnover, muscle 457–466
Transitional cell carcinoma
angiogenesis, basic fibroblast growth
factor 127–133
Tumour necrosis factor-α
fulminant hepatic failure 77–80
Tumour necrosis factor soluble receptor
fulminant hepatic failure 77–80

Uraemia
sodium, potassium pump 3–8
Urea
protein turnover, bed rest 73–75
Urea kinetics
protein requirements 215–225
Urological disease
angiogenesis, basic fibroblast growth
factor 127–133
Urothelial carcinoma
inflammation, basic fibroblast growth
factor 127–133
Uterine angiotensin receptors
pregnancy 499–505

Vascular endothelium
heart failure, psycho–neuro–immune–endocrine system 321–322
Vascular mechanics
definitions 143–146
Vascular medicine
Spain 159–160
Vascular permeability
diabetes, microangiopathy 113–117
Vascular smooth muscle
calcium, ouabain 9–12
Subject Index

Vascular structure
  Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
Vasodilating agents
  oxygen consumption/delivery relationship 105–111
Veins
  nitric oxide, pregnancy 493–497
Venous N^6-monomethyl-l-arginine
  pregnancy 493–497

Venous pooling
  orthostatic intolerance, autonomic insufficiency 277–285
Virus infection
  chronic fatigue syndrome, polymerase chain reaction 295–300

Wound healing
  burns, proteoglycans 417–425